{
    "nctId": "NCT01176916",
    "briefTitle": "Aromasin\u00ae Interventional Study Of Early Invasive Breast Cancer Patients In China",
    "officialTitle": "A PROSPECTIVE PRAGMATIC CLINICAL TRIAL OF CHINA EARLY INVASIVE BREAST CANCER PATIENTS RECEIVING ADJUVANT THERAPY WITH AROMASIN",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 564,
    "primaryOutcomeMeasure": "Time-to-Event",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.\n* ER positive.\n* The patient must be postmenopausal woman.\n* The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin\u00ae treatment (The decision to prescribe Aromasin\u00ae will necessarily precede and will be independent of the decision to enroll patients in the study).\n\nExclusion Criteria:\n\n* Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving Aromasin\u00ae treatment, there is evidence of a local relapse or distant metastasis of breast cancer, or a second primary cancer.\n* Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin\u00ae).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}